Balyasny Asset Management
BCRX icon

Balyasny Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Balyasny Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-186,125
Closed -$1.77M – 3011
2026
Q1 		$1.77M Buy
+186,125
New +$1.45M ﹤0.01% 1840
2025
Q4 		– Sell
-87,048
Closed -$661K – 3082
2025
Q3 		$661K Sell
87,048
-165,366
-66% -$1.38M ﹤0.01% 2272
2025
Q2 		$2.26M Sell
252,414
-333,792
-57% -$3.11M ﹤0.01% 1675
2025
Q1 		$4.4M Buy
586,206
+56,553
+11% +$456K 0.01% 1307
2024
Q4 		$3.98M Buy
+529,653
New +$4.02M 0.01% 1381
2024
Q1 		– Sell
-1,971,586
Closed -$11.8M – 2618
2023
Q4 		$11.8M Buy
1,971,586
+1,563,289
+383% +$9.06M 0.02% 804
2023
Q3 		$2.89M Buy
+408,297
New +$2.93M 0.01% 1279
2022
Q4 		– Sell
-1,223,721
Closed -$15.4M – 2778
2022
Q3 		$15.4M Buy
1,223,721
+29,210
+2% +$376K 0.05% 519
2022
Q2 		$12.6M Buy
+1,194,511
New +$12.3M 0.04% 571
2020
Q2 		– Sell
-3,005,676
Closed -$6.01M – 1130
2020
Q1 		$6.01M Buy
+3,005,676
New +$8.28M 0.07% 359
2018
Q1 		– Sell
-11,091
Closed -$54K – 1944
2017
Q4 		$54K Sell
11,091
-42,705
-79% -$207K ﹤0.01% 2006
2017
Q3 		$282K Buy
+53,796
New +$275K ﹤0.01% 1563
2015
Q3 		– Sell
-87,111
Closed -$1.3M – 1144
2015
Q2 		$1.3M Buy
+87,111
New +$990K 0.01% 782

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Balyasny Asset Management's BCRX Position: Q2 2026 in Review

Balyasny Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 186,125 shares — an estimated $1.77M sold.

Balyasny Asset Management first reported a position in BCRX in Q2 2015 and held it in 13 quarters. The position peaked at $15.4M in Q3 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Balyasny Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 186,125 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.77M.
  • Balyasny Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 13 quarters.
  • Balyasny Asset Management's BioCryst Pharmaceuticals position peaked at $15.4M in Q3 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.